Caren Mason - STAAR Surgical Chairman
| STAA Stock | USD 26.68 0.05 0.19% |
Chairman
Ms. Caren L. Mason serves as President, Chief Executive Officer, Director of the Company. Ms. Mason was elected to STAARs Board of Directors at its 2014 Annual Meeting, and she has served as STAARs Chief Executive Officer since March 1, 2015. From 2010 to 2012, Ms. Mason served as Chief Executive Officer of Verinata Health, Inc., a provider of noninvasive prenatal genetic sequencing tests for the early identification of fetal chromosomal abnormalities. In February 2013, Verinata was acquired by Illumina. Ms. Mason served as the President, Chief Executive Officer and a Director of Quidel Corporation from 2004 to 2009, a publicly traded company engaged in the development, anufacturing and marketing of rapid diagnostic solutions at the professional point of care in infectious diseases and reproductive health. Prior to joining Quidel, Ms. Mason provided consultative services from 2003 to 2004 for Eastman Kodak Health Imaging as a result of the sale of MiraMedica, Inc., to Eastman Kodak. She served as President and Chief Executive Officer for MiraMedica, Inc., an early phase startup developing computer aided detection software for breast cancer, from 2002 through 2003. Prior to her tenure with MiraMedica, Inc., Ms. Mason served as Chief Executive Officer of eMed Technologies of Lexington, Massachusetts, a teleradiology and picture archiving and communications systems usiness. Ms. Mason served as General Manager of the Womens Healthcare business and as a General Manager in various capacities for the Services business of General Electric Healthcare from 1996 to 2000. Ms. Masons additional healthcare experience includes her tenure with Bayer AGAGFA from 1989 to 1996 where she last held the positions of Senior Vice President for Bayer Corporationrationrate Health Care and Senior Vice President for the AGFA Technical Imaging Business Group since 2015.
| Age | 70 |
| Tenure | 9 years |
| Address | 25651 Atlantic Ocean Drive, Lake Forest, CA, United States, 92630 |
| Phone | 626 303 7902 |
| Web | https://www.staar.com |
STAAR Surgical Management Efficiency
The company has return on total asset (ROA) of 0.0339 % which means that it generated a profit of $0.0339 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of 0.054 %, meaning that it created $0.054 on every $100 dollars invested by stockholders. STAAR Surgical's management efficiency ratios could be used to measure how well STAAR Surgical manages its routine affairs as well as how well it operates its assets and liabilities. The current year's Return On Tangible Assets is expected to grow to 0.08. The current year's Return On Capital Employed is expected to grow to 0.12. At present, STAAR Surgical's Total Assets are projected to increase significantly based on the last few years of reporting. The current year's Non Current Assets Total is expected to grow to about 129.6 M, whereas Non Currrent Assets Other are forecasted to decline to about 1.8 M.Similar Executives
| Found 13 records | CHAIRMAN Age | ||
| Fred Lampropoulos | Merit Medical Systems | 74 | |
| Vincent Forlenza | Becton Dickinson and | 66 | |
| Patrick Zenner | West Pharmaceutical Services | 73 | |
| Ellen Zane | Haemonetics | 69 | |
| Vivek Jain | ICU Medical | 52 | |
| Ronald Gelbman | Haemonetics | 70 | |
| Harel Gadot | Microbot Medical | 51 | |
| George Fotiades | AptarGroup | 67 | |
| Thomas Polen | Becton Dickinson and | 51 | |
| Allan Rubenstein | The Cooper Companies, | 74 | |
| Richard Meelia | Haemonetics | 71 | |
| Stephen MacMillan | Hologic | 60 | |
| Peter Farrell | ResMed Inc | 78 | |
Management Performance
| Return On Equity | 0.054 | ||||
| Return On Asset | 0.0339 |
STAAR Surgical Leadership Team
Elected by the shareholders, the STAAR Surgical's board of directors comprises two types of representatives: STAAR Surgical inside directors who are chosen from within the company, and outside directors, selected externally and held independent of STAAR. The board's role is to monitor STAAR Surgical's management team and ensure that shareholders' interests are well served. STAAR Surgical's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, STAAR Surgical's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Nancy Sabin, Chief Officer | ||
| Brian Moore, IR Contact Officer | ||
| Warren Foust, Chief Officer | ||
| HansMartin Blickensdoerfer, President International Commercial Operations | ||
| Thomas Frinzi, CEO President | ||
| Samuel Gesten, Vice President General Counsel, Corporate Compliance Officer and Secretary | ||
| Caren Mason, CEO and President Director and Chairman of Quality and Regulatory Committee | ||
| Joanne Egamino, Global Operations | ||
| Patrick Williams, Chief Officer | ||
| Robert Studholme, Senior Operations | ||
| James Francese, VP of Global Marketing | ||
| Keith Holliday, Vice President - Research & Development | ||
| Scott MD, Chief Officer | ||
| Nathaniel Esq, General Secretary | ||
| Magda Michna, Regulatory Clinical | ||
| Philippe Subrin, Vice President - Switzerland Operations |
STAAR Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is STAAR Surgical a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | 0.054 | ||||
| Return On Asset | 0.0339 | ||||
| Profit Margin | 0.06 % | ||||
| Operating Margin | 0.06 % | ||||
| Current Valuation | 1.1 B | ||||
| Shares Outstanding | 49.28 M | ||||
| Shares Owned By Insiders | 0.53 % | ||||
| Shares Owned By Institutions | 99.13 % | ||||
| Number Of Shares Shorted | 2.92 M | ||||
| Price To Earning | 460.83 X |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether STAAR Surgical offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of STAAR Surgical's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Staar Surgical Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Staar Surgical Stock:Check out World Market Map to better understand how to build diversified portfolios, which includes a position in STAAR Surgical. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in nation. For information on how to trade STAAR Stock refer to our How to Trade STAAR Stock guide.You can also try the Portfolio Volatility module to check portfolio volatility and analyze historical return density to properly model market risk.
Is Health Care Equipment & Supplies space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of STAAR Surgical. If investors know STAAR will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about STAAR Surgical listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth 1.018 | Earnings Share 0.44 | Revenue Per Share 6.962 | Quarterly Revenue Growth 0.103 | Return On Assets 0.0339 |
The market value of STAAR Surgical is measured differently than its book value, which is the value of STAAR that is recorded on the company's balance sheet. Investors also form their own opinion of STAAR Surgical's value that differs from its market value or its book value, called intrinsic value, which is STAAR Surgical's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because STAAR Surgical's market value can be influenced by many factors that don't directly affect STAAR Surgical's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between STAAR Surgical's value and its price as these two are different measures arrived at by different means. Investors typically determine if STAAR Surgical is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, STAAR Surgical's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.